Group 1 - Company entered into a commercialization service agreement with Haisen Bio, effective December 11, 2025, to provide CSO services in China [1] - The agreement aims to create synergies in regions and customer groups not fully covered by Haisen Bio, enhancing product lifecycle management and commercialization capabilities [1] - The company expects to generate recurring service fee income from CSO services, improving the utilization and productivity of its existing commercial platform [1] Group 2 - An exclusive, non-transferable license agreement was established with Haisen Bio, allowing the company to develop, commercialize, and sell licensed compounds and products in the designated region [1] - The agreement includes limited rights to sublicense based on the licensor's patents and proprietary technology [1] Group 3 - Mr. Sun Xin has been appointed as a non-executive director, effective December 11, 2025 [2]
云顶新耀(01952)与海森生物订立商业化服务协议及授权许可协议